ASTS, CRBU and DOMO are among after hour movers [Seeking Alpha]
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
UK NICE backs Exact's Oncotype cancer genomic test Fri, May 10, 2024, 3:22 PM GMT+2 2 min read 0 In this article: Advertisement Up next These 2 ‘Strong Buy' Penny Stocks Could Surge Over 400%, Says Oppenheimer Thu, May 9, 2024, 7:20 PM GMT+2 6 min read
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update